Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Kelong HanMark BakerMark LovernProkash PaulYuan XiongParul PatelKaty P MooreCiara S SealAmy G CutrellRonald D D'AmicoPaul D BennRaphael J LandovitzMark A MarzinkeWilliam R SpreenSusan L FordPublished in: British journal of clinical pharmacology (2022)
A cabotegravir population pharmacokinetic model was developed that can be used to inform dosing strategies and future study design. No dose adjustment based on subject covariates is recommended.